Ranbaxy Admits To Infringing Purdue OxyContin Patent

By Allison Grande

Law360, New York (December 07, 2009, 8:21 PM ET) -- Ranbaxy Pharmaceuticals Inc. has admitted to infringing a Purdue Pharma LP patent for the painkiller OxyContin in a consent order resolving Purdue's suit, which had been tied to antitrust multidistrict litigation accusing Purdue of excluding generic competition for the drug through sham litigation.

Judge Sidney H. Stein of the U.S. District Court for the Southern District of New York on Friday approved a consent judgment between Purdue and Ranbaxy in which the companies agreed to settlement, patent license, and distribution and supply agreements.

The generic company...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles